Affordable Access

deepdyve-link
Publisher Website

Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.

Authors
  • Matsumoto, Kazuaki
  • Kanazawa, Naoko
  • Ikawa, Kazuro
  • Fukamizu, Tomohide
  • Shigemi, Akari
  • Yaji, Keiko
  • Shimodozono, Yoshihiro
  • Morikawa, Norifumi
  • Takeda, Yasuo
  • Yamada, Katsushi
Type
Published Article
Journal
Journal of Infection and Chemotherapy
Publisher
Elsevier
Publication Date
Jun 01, 2010
Volume
16
Issue
3
Pages
193–199
Identifiers
DOI: 10.1007/s10156-010-0038-8
PMID: 20195882
Source
Medline
License
Unknown

Abstract

An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0%. The rates of achieving >or=13 mg/L in <or=24, 24-36 and >or=36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5%, respectively. These results suggest that the administration of >or=36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of >or=13 mg/L for the initial treatment of MRSA infections.

Report this publication

Statistics

Seen <100 times